6-羟基-4-喹唑酮 | 16064-10-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-羟基-4-喹唑酮
• 中文别名: 3,4-二氢-6-羟基喹唑啉-4-酮；6-羟基-4-(3H)喹唑啉酮
• 英文名称: 6-hydroxyquinazolin-4(3H)-one
• 英文别名: 6-hydroxy-3H-quinazolin-4-one；6-hydroxy-4-quinazolinone；6-Hydroxyquinazolin-4(3H)-one
• CAS: 16064-10-1
• 化学式: C₈H₆N₂O₂
• 分子量: 162.148
• InChiKey: QJRNXXLTDWMENM-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  416.0±47.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2933990090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Hydroxy-4-quinazolone
Synonyms: 6-Hydroxyquinazolin-4(3H)-one; 6-hydroxy-4-quinazolinone; 6-hydroxyquinazolin-4-ol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Hydroxy-4-quinazolone
CAS number: 16064-10-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6N2O2
Molecular weight: 162.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-羟基-4-喹唑酮 在 吡啶 、 氯化亚砜 、 氨 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-(benzyloxy)phenyl)-6-methoxyquinazolin-4-amine
  参考文献：
  名称：

  Synthesis and SAR of potent EGFR/erbB2 dual inhibitors

  摘要：

  A series of 6-alkoxy-4-anilinoquinazoline compounds was prepared and evaluated for in vitro inhibition of the erbB2 and EGFR kinase activity. The IC50 values of the best compounds were below 0.10 uM. Further, several of these compounds inhibit the growth of erbB2 and EGFR over-expressing tumor cell lines at concentrations below I uM. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.010
• 作为产物：
  描述：

  2-氨基-5-羟基苯甲酸 、 甲酰胺 反应 0.5h， 生成 6-羟基-4-喹唑酮
  参考文献：
  名称：

  Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

  摘要：

  本发明涉及一种组合物，包括环糊精和含锌结合基衍生物的喹唑啉包含复合物。环糊精最好是β-环糊精或其衍生物。喹唑啉具有增强和意外的性质，作为表皮生长因子受体酪氨酸激酶（EGFR-TK）的抑制剂，并用于治疗EGFR-TK相关疾病和疾病，如癌症。所述衍生物还可以作为HDAC抑制剂。

  公开号：

  US08518910B2

文献信息

• [EN] NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME<br/>[FR] NOUVEAUX ACTIVATEURS DE LA GLUCOKINASE ET MÉTHODES D'UTILISATION DESDITS ACTIVATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011130459A1

  公开（公告）日：2011-10-20

  Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R1, R2, R3, R4, R5, R6, Y and X are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related disease employing the above compounds is also provided.

  提供了一些化合物，这些化合物是葡萄糖激酶的激活剂，因此在治疗糖尿病和相关疾病方面很有用，这些化合物的结构式中，R1、R2、R3、R4、R5、R6、Y和X如本文所述，或其药用可接受盐。还提供了一种使用上述化合物治疗糖尿病和相关疾病的方法。
• Aniline derivatives
  申请人：Zeneca Limited

  公开号：US05821246A1

  公开（公告）日：1998-10-13

  The invention concerns aniline derivatives of formula I ##STR1## wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R.sup.1 and R.sup.2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.

  本发明涉及公式I的苯胺衍生物：##STR1##，其中m为1、2或3，n为0、1、2或3，Q为苯基或萘基或含氧、氮、硫的1、2或3个杂原子的5或6元杂芳基基团，X、R1和R2的定义见权利要求；或包含它们的药物组合物，以及使用该化合物作为酪氨酸激酶抑制剂和治疗诸如癌症的增殖性疾病的方法。
• 作为欧若拉激酶抑制剂的取代喹唑啉类衍生 物
  申请人：广东东阳光药业有限公司

  公开号：CN104098551B

  公开（公告）日：2019-03-22

  本发明涉及用于抑制欧若拉激酶的如式（I）或（Ia）所示的取代喹唑啉类衍生物及其互变异构体、水合物、溶剂化物或药学上可接受的盐，和含有这些化合物作为活性成分的药物组合物，以及所述化合物及其药物组合物来制备用于防护，处理，治疗或减轻患者增殖性疾病的药物的用途。
• HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability
  作者：Tamer A. Elwaie、Safinaz E. Abbas、Enayat I. Aly、Riham F. George、Hamdy Ali、Nikolai Kraiouchkine、Khaldoun S. Abdelwahed、Tamer E. Fandy、Khalid A. El Sayed、Zakaria Y. Abd Elmageed、Hamed I. Ali

  DOI：10.1021/acs.jmedchem.0c01647

  日期：2020.12.24

  developed derivatives demonstrated potent and selective inhibitions (IC50: 5.4–12 nM) compared to lapatinib (IC50: 95.5 nM). Favorably, 17d exhibited minimum off-target kinase activation. NCI-5-dose screening revealed broad-spectrum activities (GI50: 1.43–2.09 μM) and 17d had a remarkable selectivity toward BC. Our compounds revealed significant selective and potent antiproliferative activities (∼20-fold)

  HER2激酶作为公认的乳腺癌（BC）治疗靶标与积极的临床疗效相关；因此，本文中我们提出了针对HER2选择性靶向的结构优化。与拉帕替尼（IC 50：95.5 nM）相比，已开发衍生物的HER2分析显示出有效和选择性的抑制作用（IC 50：5.4–12 nM）。有利地，17d表现出最小的脱靶激酶激活。NCI-5剂量筛选显示广谱活性（GI 50：1.43-2.09μM），而17d对BC具有显着的选择性。与HER2（-）细胞相比，我们的化合物显示出对HER2 +（AU565，BT474）的显着选择性和强效抗增殖活性（约20倍）。在0.1 IC 50时，15i，17d和25b通过免疫印迹抑制pERK1 / 2和pAkt。此外，17d证明了针对BT474异种移植模型的有效体内肿瘤消退。值得注意的是，在媒介物中观察到转移病例，但在测试小鼠组中未观察到转移病例。CD-1小鼠代谢稳定性测定显示17d具有较高的稳定性和较低的固有清除率（T
• TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20090076022A1

  公开（公告）日：2009-03-19

  The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.

  本发明涉及含有锌结合基团的喹唑啉酸盐衍生物，这些衍生物是表皮生长因子受体酪氨酸激酶（EGFR-TK）的抑制剂，以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。这些酒石酸盐还可能作为HDAC抑制剂。